Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | FGFR2 - KIAA1217 FGFR2 L550F |
Therapy | Infigratinib |
Indication/Tumor Type | cholangiocarcinoma |
Response Type | predicted - resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 - KIAA1217 FGFR2 L550F | cholangiocarcinoma | predicted - resistant | Infigratinib | Case Reports/Case Series | Actionable | In a clinical case study, a patient with cholangiocarcinoma harboring an FGFR2-KIAA1217 fusion experienced disease progression after 6.6 months of treatment with Truseltiq (infigratinib) and was found to have acquired an FGFR2 L550F mutation (PMID: 34250419). | 34250419 |
PubMed Id | Reference Title | Details |
---|---|---|
(34250419) | Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations. | Full reference... |